Saturday, July 11, 2026

pharma · Peanut allergy · Allergy, Peanut

DBV Technologies

DBV Technologies clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Chatillon, FR HQ
220 Employees
EMA registrant Type
Company details
Status
Public
HQ
Chatillon, FR
Employees
220
Programs
3
Drugs
7
Patents
0
Intelligence · Clinical Programs

DBV Technologies projects

3 ClinicalTrials.gov programs sponsored by DBV Technologies.

DBV Technologies has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. DBV712

    DBV Technologies

    Allergy, Peanut

    phase 3 small molecule active

    1 trial
  2. V712-305/EPOPEX

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial
  3. V712-308

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does DBV Technologies have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.